Description
Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai, is joined by Fred M. Kusumoto, MD, FHRS, Mayo Clinic Jacksonville, and Julia H. Indik, MD, PhD, FHRS, University of Arizona Medical Center (CVD) to discuss how Atrial fibrillation (AF) is a chronic progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia.
Learning Objectives
- To discern whether or not catheter ablation modifies the pathogenic mechanism of AF progression.
Article Authors and Podcast Contributors
Article Authors
Jason G. Andrade, Marc W. Deyell, Paul Khairy, Jean Champagne, Peter Leong-Sit, Paul Novak, Lawrence Sterns, Jean-Francois Roux, John Sapp, Richard Bennett, Matthew Bennett , Nathaniel Hawkins, Prashanthan Sanders, and Laurent Macle
Podcast Contributors
Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai
Fred M. Kusumoto, MD, FHRS, Mayo Clinic Jacksonville
Julia H. Indik, MD, PhD, FHRS, University of Arizona Medical Center (CVD)
Disclosure Policy
ACE Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
All relevant financial relationships have been mitigated.
Host Disclosure(s):
J. Chyou: Honoraria/Speaking/Consulting: McGraw-Hill, American Heart Association, Membership, Advisory Committee: American Heart Association
Contributor Disclosure(s):
J. Indik: Honoraria, Other Financial Relationships: American College of Cardiology, Honoraria/Speaking/Consulting: Heart Rhythm Society
F. Kusumoto: Nothing to disclose
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.